Pharming Group N.V. (PHAR) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

13/25

Growth 3 Margin 2 Expansion 4 Platform 1 Financial 3

latest quarter score

Earnings Reports

13
Pharming (PHAR) Q2 2026: Joenja Grows 40% as Pipeline Readouts Set Up Multi-Billion Opportunity
July 30, 2026
20
Pharming Group (PHAR) Q1 2026: Joenja Grows 34% as Pediatric and Global Launches Drive Expansion
May 07, 2026
22
Pharming Group (PHAR) Q4 2025: Joenja Surges 53% as U.S. Drives 75% of Growth
March 13, 2026
20
Pharming Group (PHAR) Q3 2025: Ruconest Drives 29% Growth as Guidance Raised on Rare Disease Expansion
November 06, 2025
22
Pharming (PHAR) Q2 2025: Ruconest Drives 28% Growth as APDS Pipeline Expands
July 31, 2025
18
Pharming (PHAR) Q1 2025: Ruconest Jumps 49% as Pipeline Expansion and Cost Discipline Reshape Outlook
July 05, 2025
16
Pharming Group (PHAR) Q4 2024: 21% Revenue Growth Accelerates Rare Disease Portfolio Expansion
March 13, 2025

Browse all companies